Hudkins Robert L, Diebold James L, Tao Ming, Josef Kurt A, Park Chung Ho, Angeles Thelma S, Aimone Lisa D, Husten Jean, Ator Mark A, Meyer Sheryl L, Holskin Beverly P, Durkin John T, Fedorov Alexander A, Fedorov Elena V, Almo Steven C, Mathiasen Joanne R, Bozyczko-Coyne Donna, Saporito Michael S, Scott Richard W, Mallamo John P
Discovery Research, Cephalon, Incorporated, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, USA.
J Med Chem. 2008 Sep 25;51(18):5680-9. doi: 10.1021/jm8005838. Epub 2008 Aug 21.
The optimization of the dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-one R(2) and R(12) positions led to the identification of the first MLK1 and MLK3 subtype-selective inhibitors within the MLK family. Compounds 14 (CEP-5104) and 16 (CEP-6331) displayed good potency for MLK1 and MLK3 inhibition with a greater than 30- to 100-fold selectivity for related family members MLK2 and DLK. Compounds 14 and 16 were orally active in vivo in a mouse MPTP biochemical efficacy model that was comparable to the first-generation pan-MLK inhibitor 1 (CEP-1347). The MLK1 structure-activity relationships were supported by the first-reported X-ray crystal structure of MLK1 bound with 16.
对二氢萘并[3,4-a]吡咯并[3,4-c]咔唑-5-酮的R(2)和R(12)位进行优化,从而鉴定出了丝裂原活化蛋白激酶激酶(MLK)家族中首个MLK1和MLK3亚型选择性抑制剂。化合物14(CEP-5104)和16(CEP-6331)对MLK1和MLK3具有良好的抑制活性,对相关家族成员MLK2和DLK的选择性大于30至100倍。在小鼠MPTP生化效应模型中,化合物14和16在体内具有口服活性,与第一代泛MLK抑制剂1(CEP-1347)相当。首次报道的与16结合的MLK1的X射线晶体结构支持了MLK1的构效关系。